It has been revealed that PPAR -γ agonist pioglitazone protects against IL-17-induced intervertebral disc inflammation and degeneration via suppression of the NF-κB signaling pathway, which may provide a novel perspective on PPAR-γ agonist as a potential treatment for IDD [36]. The gene discussed is PPARG; the disease is intervertebral disk degenerative disorder.